Sunitinib Study in Pancreatic Cancer Stopped Early After Significant Benefit Seen

Publication
Article
OncologyONCOLOGY Vol 23 No 4
Volume 23
Issue 4

A phase III clinical trial of sunitinib (Sutent) has been stopped early after the drug showed significant benefit in patients with advanced pancreatic neuroendocrine tumors. An independent data monitoring committee recommended halting the trial after concluding that sunitinib demonstrated greater progression-free survival compared with placebo plus best supportive care in these patients.

A phase III clinical trial of sunitinib (Sutent) has been stopped early after the drug showed significant benefit in patients with advanced pancreatic neuroendocrine tumors. An independent data monitoring committee recommended halting the trial after concluding that sunitinib demonstrated greater progression-free survival compared with placebo plus best supportive care in these patients.

All patients in the trial will have the option to continue taking sunitinib or be switched from placebo to sunitinib. The full data set from this trial is being analyzed and more details will be presented at an upcoming scientific meeting.

Articles in this issue
Despite Past Disappointments the Future of Melanoma Therapy Appears Bright
Everolimus Approved for Advanced Kidney Cancer
Report Shows Record Number of Cancer Drugs in Development
Sunitinib Study in Pancreatic Cancer Stopped Early After Significant Benefit Seen
Black Cohosh (Cimicifuga racemosa)
Black Cohosh (Cimicifuga racemosa)
Clinical Trials and Radiation Oncology Technologies
Evaluating Advanced Technologies in Radiation Oncology: When and How Should Randomized Trials Be Done?
Current Status and Future Potential of Advanced Technologies in Radiation OncologyPart 2. State of the Science by Anatomic Site
Health Literacy: Improving Patient Understanding
Health Literacy, Communication, and Treatment Decision-Making in Older Cancer Patients
The Role of Adjuvant Radiation in Endometrial Cancer
The Role of Adjuvant Radiation in Endometrial Cancer
Resolving the Confusion Surrounding Adjuvant Radiation in Endometrial Cancer
Studies of Adjuvant Treatment for Endometrial Cancer
Landmark Study Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer
Maintenance Rituximab Useful in Advanced Indolent Lymphoma
Recent Videos
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Related Content
Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.

Advancing Pancreatic Cancer Care Through Intraoperative Radiation Therapy

Kamran Idrees, MD, MSCI, MMHC, FACS ;Natalie A. Lockney, MD;Milad Baradaran, PhD, DABR
August 5th 2024
Podcast

Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.

Addressing Gaps in Education for Non–Clear Cell RCC

Addressing Gaps in Education for Non–Clear Cell RCC

ONCOLOGY Staff
November 19th 2024
Article

A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Diane M. Simeone, MD “Thrilled” To Be UCSD Moores Cancer Center Director

Diane Simeone, MD
February 26th 2024
Podcast

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Managing Pancreatic Cancer Through Risk Factors, Diagnosis, and AEs

Managing Pancreatic Cancer Through Risk Factors, Diagnosis, and AEs

Tim Cortese
November 18th 2024
Article

A nurse practitioner gives a closer look into the risk factors, diagnosis, adverse effects, and future treatments associated with pancreatic cancer.

Using Real-World Data to Form GPRC5D Therapy Strategies in R/R Multiple Myeloma

Using Real-World Data to Form GPRC5D Therapy Strategies in R/R Multiple Myeloma

ONCOLOGY Staff
November 18th 2024
Article

Experts in multiple myeloma discussed real-world efficacy and safety data associated with the use of GPRC5D-targeting bispecific agents to treat patients with R/R multiple myeloma.